FY2024 Earnings Estimate for Savara Issued By HC Wainwright

Savara Inc (NASDAQ:SVRA) – HC Wainwright boosted their FY2024 earnings per share estimates for Savara in a research note issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.46) per share for the year, up from their previous estimate of ($0.48). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Savara’s Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at $0.00 EPS.

Several other research firms have also commented on SVRA. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a report on Tuesday, October 1st. Evercore ISI reiterated an “in-line” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Savara in a report on Wednesday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Stock Down 6.6 %

Shares of NASDAQ SVRA opened at $2.98 on Friday. The stock has a market cap of $511.43 million, a P/E ratio of -6.86 and a beta of 1.02. The business’s fifty day simple moving average is $3.91 and its 200-day simple moving average is $4.20. Savara has a 12-month low of $2.83 and a 12-month high of $5.70. The company has a current ratio of 17.70, a quick ratio of 11.31 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting analysts’ consensus estimates of ($0.11).

Institutional Investors Weigh In On Savara

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. lifted its stake in shares of Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after acquiring an additional 3,443,541 shares in the last quarter. Farallon Capital Management LLC lifted its position in Savara by 90.5% during the 2nd quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company’s stock worth $18,377,000 after acquiring an additional 2,165,701 shares in the last quarter. First Light Asset Management LLC purchased a new position in Savara in the 2nd quarter worth approximately $8,069,000. Finally, Wellington Management Group LLP grew its position in Savara by 22.9% in the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock valued at $36,566,000 after acquiring an additional 1,608,522 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.